Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 2/20 | 0.42 |
| ▸ | WEE1 | P30291 | 1/20 | 0.42 |
| ▸ | SYK | P43405 | 6/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | APAF1 | O14727 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | ULK1 | O75385 | 3/20 | 0.40 |
| ▸ | AGPAT2 | O15120 | 1/20 | 0.39 |
| ▸ | IGF1R | P08069 | 4/20 | 0.39 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5068326 | 0.77 | KDM4E (0.40) | CDC7WEE1SYKALDH1A1HSD17B10 | |
| SCHEMBL2071594 | 0.76 | ULK1 (0.47) | CDC7SYKULK1IGF1R | |
| SCHEMBL13636071 | 0.76 | CDC7 (0.50) | CDC7WEE1SYKALDH1A1HSD17B10 | |
| SCHEMBL4952013 | 0.75 | ULK1 (0.51) | CDC7SYKULK1IGF1R | |
| SCHEMBL5070933 | 0.74 | CDC7 (0.42) | CDC7WEE1SYKALDH1A1HSD17B10 | |
| SCHEMBL2071141 | 0.74 | ULK1 (0.44) | CDC7SYKULK1IGF1R | |
| SCHEMBL15208658 | 0.71 | CLK1 (0.43) | SYKALDH1A1KDM4EMAPTAPAF1 | |
| SCHEMBL13636077 | 0.71 | SYK (0.48) | CDC7WEE1SYKALDH1A1HSD17B10 | |
| SCHEMBL12431097 | 0.70 | ULK1 (0.50) | CDC7WEE1SYKALDH1A1HSD17B10 | |
| SCHEMBL3703992 | 0.69 | SYK (0.44) | CDC7WEE1SYKALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080287444-A1 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2008-11-20 | — | — | US | claimed |
| EP-1345929-B1 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMA (US) | 2006-05-17 | — | — | EP | claimed |
| US-20040157893-A1 | Pyrazole compounds useful as protein kinase inhibitors | BEBBINGTON DAVID (GB) | 2004-08-12 | — | — | US | claimed |
| US-6656939-B2 | Anticancer agents; autoimmune diseases | VERTEX PHARMACEUTICALS INCORPORATED | 2003-12-02 | — | — | US | claimed |
| US-20030004164-A1 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2003-01-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004164-A1 | Pyrazole compounds useful as protein kinase inhibitors | AURKC, AURKA, GSK3B | CDC7 30/4885WEE1 63/4885SYK 1327/4885 |
| US-20080287444-A1 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | AURKC, AURKA, CDK3 | CDC7 52/4885WEE1 47/4885SYK 1153/4885 |
| US-20040157893-A1 | Pyrazole compounds useful as protein kinase inhibitors | AURKC, AURKA, GSK3B | CDC7 30/4885WEE1 64/4885SYK 1242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.